AJANTPHARM
Ajanta Pharma
Each stock's 10,000-path forecast, rendered as light.
Ajanta Pharma (AJANTPHARM) Stock Analysis & Case Study
Is AJANTPHARM a good buy? The data-driven verdict.
Ajanta Pharma (AJANTPHARM) trades at ₹3,190,on the numbers it worth a closer look, a Downstox Snapshot Score of 66/100.
On the numbers, Ajanta Pharma (AJANTPHARM) worth a closer look, a Downstox Snapshot Score of 66/100, weighing premium at 35.3× earnings, ROE of 27.1%, a 61% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
AJANTPHARM fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is AJANTPHARM overvalued? AJANTPHARM P/E vs its sector
AJANTPHARM's P/E of 35.3× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.88% dividend yield is below the peer median of 1.65%.
AJANTPHARM share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of AJANTPHARM history (14%/yr drift, 32%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| AJANTPHARM 2027 | ₹2,230 | ₹3,348 | ₹5,099 | +9% |
| AJANTPHARM 2028 | ₹2,037 | ₹3,695 | ₹6,564 | +21% |
| AJANTPHARM 2029 | ₹1,974 | ₹4,029 | ₹8,199 | +31% |
| AJANTPHARM 2030 | ₹1,965 | ₹4,348 | ₹10,090 | +42% |
| AJANTPHARM 2031 | ₹1,957 | ₹4,762 | ₹12,090 | +55% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability AJANTPHARM goes up, or doubles?
The bull case for AJANTPHARM
- High return on equity (27.1%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- Strong ROCE (34.5%) shows the core business earns well above its cost of capital.
- A 10,000-path probability model puts a 61% chance the price is higher in a year, with a median target of ₹3,348 (+9%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹8,199.
The bear case & risks
- At 35.3× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.
- A steep 8.8× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,974.
AJANTPHARM volatility & expected range, how bumpy is the ride?
Over the last 2.0 years AJANTPHARM compounded at 14%/year with annualized volatility of 32%. That volatility implies a 1-year 80% range of ₹2,230–₹5,099, the honest backbone behind any single price target.
AJANTPHARM price forecast, the full 60-month probability fan
AJANTPHARM price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds AJANTPHARM hits common targets within the simulated horizon?
Full multi-horizon detail on the AJANTPHARM price target & forecast page.
AJANTPHARM Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. AJANTPHARM scores 4/9,mixed financial health.
AJANTPHARM MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy AJANTPHARM with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 29.0% | 3.5× |
| ZerodhaCHEAPEST | 29.0% | 3.5× |
| DhanCHEAPEST | 29.0% | 3.5× |
Compare every broker on the AJANTPHARM MTF page.
AJANTPHARM vs peers,sector comparison
About Ajanta Pharma: sector, index & market-cap context
Ajanta Pharma (AJANTPHARM) is a mid-cap NSE-listed company, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹39,884 Cr. See more Nifty 100 stocks.
How the AJANTPHARM Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Ajanta Pharma's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
AJANTPHARM analysis, FAQs
Is Ajanta Pharma (AJANTPHARM) a good buy?
On the numbers, Ajanta Pharma (AJANTPHARM) worth a closer look, a Downstox Snapshot Score of 66/100, weighing premium at 35.3× earnings, ROE of 27.1%, a 61% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is AJANTPHARM overvalued or undervalued?
AJANTPHARM trades at 35.3× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the AJANTPHARM share price target for 2031?
AJANTPHARM's probability-weighted 2031 median target is ₹4,762, with an 80% range of ₹1,957–₹12,090 (10,000-path Monte-Carlo).
What is the probability AJANTPHARM doubles in 5 years?
The modelled probability of AJANTPHARM reaching ₹6,130 (2×) within 5 years is 36%.
What is the bull case for AJANTPHARM?
High return on equity (27.1%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. Strong ROCE (34.5%) shows the core business earns well above its cost of capital. A 10,000-path probability model puts a 61% chance the price is higher in a year, with a median target of ₹3,348 (+9%).
What are the risks in AJANTPHARM?
At 35.3× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished. A steep 8.8× price-to-book means most of the value is intangible/expectations, not assets on the books.